前沿论文｜CELL INTELLIGENCE

Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.

PubMed 2026/08/10 发表Future Sci OAQ3 · IF 2.5（JCR 2025）

Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.

PubMed 2026/06/30 发表Mol Ther OncolQ1 · IF 8.5（JCR 2025）

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.

PubMed 2026/05/27 发表Hum Gene TherQ1 · IF 4.6（JCR 2025）

Next-generation CAR-NK cell therapy for glioblastoma: strategies to overcome antigen escape and the immunosuppressive tumor microenvironment.

PubMed 2026/05/11 发表Expert Opin Biol TherQ2 · IF 4（JCR 2025）

Targeting the COX-2/PGE(2) axis to enhance NK and T cell immunotherapy in brain tumors.

PubMed 2026/04/10 发表Cancer Immunol ImmunotherQ1 · IF 5.8（JCR 2025）

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.

PubMed 2026/04/09 发表Nat CommunQ1 · IF 18.1（JCR 2025）

Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma.

PubMed 2026/03/25 发表Cell Death DifferQ1 · IF 13.6（JCR 2025）

The Gut-Brain-Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities.

PubMed 2026/02/12 发表Cell Mol NeurobiolQ1 · IF 7.4（JCR 2025）

Integrative Analysis of Cytotoxic Lymphocytes-Mediated Tumour Killing Related Genes Reveals LDHA as a Novel Glioblastoma Therapeutic Target.

PubMed 2026/02/01 发表J Cell Mol MedQ2 · IF 4.7（JCR 2025）

CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.

PubMed 2026/01/20 发表Curr Probl CancerQ3 · IF 2.4（JCR 2025）

前沿论文 38